ClinicalTrials.gg
TerminatedNCT05300048Updated Apr 30, 2026

Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations

A Phase 1 interventional study of Serabelisib and Insulin Suppressing Diet in Advanced Solid Tumor, PIK3CA Mutation and PTEN Loss of Function Mutation, sponsored by Faeth Therapeutics. Terminated at 17 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by Faeth Therapeutics · Phase 1, Interventional, and Treatment

Why this study was terminated
Program prioritization

From the registry’s dates

  • Primary completion was Apr 2025, 1 year 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
34
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will evaluate the feasibility of optimizing the safety and tolerability of serabelisib (an investigational PI3K inhibitor) when combined with an ISD and with or without nab-paclitaxel with a goal of reducing side effects and enhancing anticancer activity.

Read the detailed description

Targeted anticancer drugs have side effects that often result in a poor quality of life, noncompliance, dose decreases, or discontinuation, all of which can affect efficacy. This study will evaluate the feasibility of optimizing the safety and tolerability of serabelisib when combined with an insulin suppressing diet and with or without nab-paclitaxel with a goal of reducing side effects and enhancing anticancer activity.

02

Conditions studied

  • Advanced Solid Tumor
  • PIK3CA Mutation
  • PTEN Loss of Function Mutation

Keywords

  • PIK3CA Mutation
  • PTEN Loss of Function Mutation
03

In context

Lead sponsor

Faeth Therapeutics is the lead sponsor of 6 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to provide written .
  2. Age ≥18 at Visit -1 (screening).
  3. or cytologically confirmed recurrent solid tumors.

    1. Cohort 1a: any extracranial solid tumor (may include EC, ovarian clear cell, or ovarian endometrioid carcinoma if subject is not eligible for nab-paclitaxel in Cohort

      1b)

    2. Cohort 1b: either recurrent or persistent endometrial adenocarcinoma (EC) with the following histologic epithelial cell types: endometrioid adenocarcinoma, serous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, adenocarcinoma not otherwise specified (N.O.S.), mucinous adenocarcinoma, squamous cell carcinoma, transitional cell carcinoma, and carcinosarcoma or; ovarian cancer (OC) with the primary tumor having ≥ 50% clear cell histomorphology or ovarian clear cell or ovarian endometrioid carcinoma.
    3. Cohort 2: adenocarcinoma of the colon or rectum.
    4. Cohort 3: recurrent or persistent endometrial adenocarcinoma with the following histologic epithelial cell types as described for Cohort 1b
    5. Cohort 4: OC primary tumor carcinomas as described for Cohort 1b
  4. Tumor must harbor an activating mutation in the PIK3CA gene with or without PTEN loss, either previously documented or determined during screening.
  5. Fresh or archival tumor with sufficient material to be sent to the designated laboratory for PD analyses. For subjects who consent to future research, an additional 5 slides from a surgical specimen or biopsy is required.
  6. Cohort 1a - Dose Modification (subjects with any solid tumor): failed, were intolerant of, or ineligible for no more than three (LOT) for advanced/ disease or refused SOC therapy.
  7. For all cohorts, in the unlikely scenario that a subject refused all available SOC they may proceed with trial. These subjects would be regarded as having 0 prior LOT.
  8. Cohorts 1b, 2, 3, and 4 - failed, were intolerant of, ineligible for, or have refused SOC therapy for advanced/metastatic disease (AJCC stage III and IV) and:

    1. Cohort 2 (subjects with colorectal cancer): Have failed no more than two prior LOT for metastatic CRC.
    2. Cohort 1b, and Cohort 3 (subjects with EC): Have no more than three prior chemotherapeutic regimens for management of endometrial carcinoma ( and/or adjuvant chemotherapy will be counted as one prior LOT). Prior hormonal therapy will not count as a systemic regimen.
    3. Cohort 1b, and Cohort 4 (subjects with clear cell or endometrioid OC): Subjects must have had no more than three prior chemotherapeutic regimens for management of ovarian carcinoma. Prior hormonal therapy will not count as a systemic regimen.
  9. of at least 3 months.
  10. At least one (as defined by [RECIST] 1.1).
  11. PS of 0 to 1.
  12. Adequate organ function

    1. (ANC) ≥1.0 × 10\^9/L or ≥1.5 x 10\^9/L if planned to be treated with nab-paclitaxel, count ≥75 × 10\^9/L, and ≥8.5 gm/dL (may be transfused to reach this hemoglobin level unless due to blood loss).
    2. Liver transaminases ( and ALT) ≤2.5 × (ULN) (\<5 × ULN if liver metastases are present), and total ≤1.5 × ULN (\<3 x ULN if subject has Gilbert Syndrome).
    3. ≤1.5 x ULN unless subject is on anticoagulants that would affect the INR, then INR must be in the desired therapeutic range as judged by the Investigator.
    4. Albumin level ≥3.0 mg/dL or ≥ the lower limit of normal.
    5. Renal: Serum creatinine ≤2 x ULN
  13. Ability to take PO medication, be willing to adhere to study procedures and Study Intervention administration, and receive, consume, and comply with Study ISD.
  14. For women of , a negative serum pregnancy test collected at screening (Visit-1) and negative urine pregnancy test collected at baseline (Visit-1) and use of physician-approved method of from the time of the pregnancy test performed at screening to 90 days following the last administration of Study Drug or, if applicable, 6 months following the last administration of nab-paclitaxel.
  15. Male subjects must be surgically sterile or must agree to use physician-approved contraception during the study and for 90 days following the last administration of Study Drug.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of primary malignant brain tumor.
  2. Has had serabelisib, alpelisib, or other PI3K inhibitor.
  3. and symptomatic or untreated .
  4. Diagnosis of, or requiring treatment for, another within the past 2 years (excluding a history of carcinoma in situ of the cervix, superficial non-melanoma skin cancer, or superficial bladder cancer that has been adequately treated, or stage 1 prostate cancer that does not require treatment or requires only treatment with luteinizing hormone-releasing hormone agonists or antagonists if initiated at least 90 days prior to the first dose of Study Drug).
  5. Is less than 21 days from therapeutic radiation or chemotherapy prior to the first day of dosing with Study Drug and has not recovered to Grade ≤ 1 from all toxicities related to prior therapies.
  6. For subjects receiving nitrosoureas or mitomycin C, the subject is \< 6 weeks from last dose. For monoclonal antibody therapy, the subject is \< 1 half-life or \<4 weeks from the last dose.
  7. Chronic, systemically administered in doses equivalent to >5 mg prednisone daily. Replacement corticosteroids for adrenal insufficiency are permitted.
  8. Diabetes mellitus requiring insulin or insulin secretagogue therapy.
  9. Poorly controlled diabetes mellitus defined as glycosylated (HbA1c) >7.5% or fasting blood sugar >160 mg/ dL.
  10. Known impaired cardiac function or clinically significant cardiac disease.
  11. interval >470 msec found at screening.
  12. Myocardial infarction, cardiac stent placement, or unstable angina within 6 months before the first administration of Study Drug.
  13. Have clinically significant peripheral vascular disease.
  14. Manifestations of malabsorption
  15. Other clinically significant comorbidities.
  16. Pregnant (positive serum pregnancy test), planning to become pregnant during the study, or breastfeeding/planning to breastfeed during the study.
  17. Have taken strong inducers/inhibitors within 7 days before the first administration of serabelisib or have conditions that require the concomitant use of CYP3A4 inducers/inhibitors.
  18. Untreated or poorly controlled, gastro-esophageal reflux disease.
  19. Have taken histamine-H2 receptor antagonists within 12 hours before the first administration of serabelisib.
  20. Have taken PPI within 7 days or 5 half-lives (whichever is the shorter duration) before the first administration of serabelisib or are anticipated to need PPI during the study.
  21. Have taken neutralizing antacids within 4 hours before the first administration of serabelisib or are anticipated to need frequent antacid use during the study.
  22. Subjects with poorly controlled , virus, and/or virus infections.
  23. Known allergies to nab-paclitaxel or , serabelisib or excipients or the ISD
  24. Severe, uncontrolled gout.
  25. A \<18.5 kg/m2, or serious or refractive cachexia or anorexia that, in the Investigator's opinion, realistically prohibits subjects from having energy or appetite sufficient to reliably engage in a strict ISD regimen for an extended time.
  26. Any condition that renders the subject unable to satisfactorily chew, swallow, digest, or tolerate (i.e., persistent diarrhea) the majority of foods and liquids of the Study ISD.
  27. History of severe nephrolithiasis requiring urologic intervention.
  28. Participation in a diet or weight loss plan within 10 days prior to the first administration of Study Drug.
  29. Severe constipation or condition where exacerbation of constipation is not advisable (eg, small bowel obstruction history).
  30. History of anaphylaxis from food allergy or other disease state requiring avoidance of a particular food, such as celiac disease.
  31. Diagnosed eating disorder in the past 10 years.
  32. Unwilling to take a non-vegan or non-vegetarian diet.
  33. Peripheral neuropathy ≥ CTC Grade 2
Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Cohort 1a - Dose Modification without nab-paclitaxel

    Subjects with any solid tumor will receive multiple doses of serabelisib administered orally and will consume Insulin Suppressing Diet for up to 12 months

    Drug: Serabelisib · Other: Insulin Suppressing Diet

  • Experimental
    Cohort 1b - Dose Modification with Nab-Paclitaxel

    Subjects with endometrial cancer, ovarian clear cell or ovarian endometriod carcinoma will receive multiple doses of serabelisib administered orally and will consume Insulin Suppressing Diet for up to 12 months. In addition, these subjects will receive nab-paclitaxel intravenously weekly.

    Drug: Serabelisib · Other: Insulin Suppressing Diet · Drug: Nab paclitaxel

  • Experimental
    Cohort 2 - Expansion Colorectal Cancer

    Subjects will receive dose of serabelisib as determined from Cohort 1a and 1b, and will consume Insulin Suppressing Diet for up to 12 months

    Drug: Serabelisib · Other: Insulin Suppressing Diet

  • Experimental
    Cohort 3 - Expansion Endometrial Cancer

    Subjects will receive dose of serabelisib as determined from Cohort 1a and 1b, and will consume Insulin Suppressing Diet for up to 12 months. If results from Cohort 1b show a favorable risk-benefit ratio, nab-paclitaxel will be administered intravenously weekly.

    Drug: Serabelisib · Other: Insulin Suppressing Diet · Drug: Nab paclitaxel

  • Experimental
    Cohort 4 - Expansion Ovarian Clear Cell or Ovarian Endometrioid Carcinoma

    Subjects will receive dose of serabelisib as determined from Cohorts 1a and 1b, and will consume Insulin Suppressing Diet for up to 12 months. If results from Cohort 1b show a favorable risk-benefit ratio, nab-paclitaxel will be administered intravenously weekly.

    Drug: Serabelisib · Other: Insulin Suppressing Diet · Drug: Nab paclitaxel

Interventions

  • serabelisib administered orally

  • OtherInsulin Suppressing Diet

    3 meals consumed daily (i.e., breakfast, lunch, dinner) and optional snacks provided dependent on caloric needs

  • nab-paclitaxel administered intravenously weekly

06

What researchers measure

Primary outcomes

  1. Cohorts 1a/1b: Evaluate safety

    Incidence of related AEs

    Time frame: Through study completion, up to 12 months.

  2. Cohorts 1a/1b: Evaluate compliance

    Compliance of Study intervention

    Time frame: Through study completion, up to 12 months.

  3. Cohorts 1a/1b: Evaluate the pharmacokinetic impact by measuring Cmax.

    Standard pharmacokinetic parameters (Cmax)

    Time frame: Through study completion, up to 12 months.

  4. Cohorts 1a/1b: Evaluate the pharmacokinetic impact by measuring Tmax.

    Standard pharmacokinetic parameters (Tmax).

    Time frame: Through study completion, up to 12 months.

  5. Cohorts 1a/1b: Evaluate the pharmacokinetic impact by measuring AUC.

    Standard pharmacokinetic parameters (AUC).

    Time frame: Through study completion, up to 12 months.

  6. Cohorts 2, 3, 4: Use the Objective Response Rate (ORR) to assess the antitumor efficacy of serabelisib in combination with a Study ISD.

    Proportion of subjects who have best overall response of either complete response (CR) or partial response (PR)

    Time frame: Through study completion, an average of 8 months.

Secondary outcomes

  1. Cohorts 1a/1b: Antitumor efficacy of study intervention by measuring ORR.

    Proportion of subjects who have best overall response of either CR or PR, as determined by each site.

    Time frame: Through study completion, up to 12 months.

  2. Cohorts 1a/1b: Antitumor efficacy of study intervention by measuring PFS.

    Time from date of first dose of Study Drug (Visit 1) to the date of first evidence of disease progression or death from any cause (whichever occurs first).

    Time frame: Through study completion, up to 12 months.

  3. Cohorts 1a/1b: Antitumor efficacy of study intervention by measuring OS.

    Overall survival (OS) and landmark survival.

    Time frame: Through study completion, up to 12 months.

  4. Cohorts 1a/1b: Antitumor efficacy of study intervention by measuring DoR.

    Duration of response (DoR)

    Time frame: Through study completion, up to 12 months.

  5. Cohorts 1a/1b: Antitumor efficacy of study intervention by measuring DCR.

    Disease control rate (DCR; CR + PR + stable disease \[SD\])

    Time frame: Through study completion, up to 12 months.

  6. Cohort 2, 3, 4: Confirm safety

    Incidence of related AEs

    Time frame: Through study completion, up to 12 months.

  7. Cohort 2, 3, 4: Confirm the compliance of study intervention.

    Compliance of Study intervention

    Time frame: Through study completion, up to 12 months.

  8. Cohort 2, 3, 4: Additional assessments of antitumor efficacy of study intervention (Measuring PFS).

    Time from the date of first dose of Study Drug (Visit 1) to the date of first evidence of disease progression or death from any cause (whichever occurs first)

    Time frame: Through study completion, up to 12 months.

  9. Cohort 2, 3, 4: Additional assessments of antitumor efficacy of study intervention (Measuring OS).

    OS and landmark survival

    Time frame: Through study completion, up to 12 months.

  10. Cohort 2, 3, 4: Additional assessments of antitumor efficacy of study intervention (Measuring DoR).

    DoR

    Time frame: Through study completion, up to 12 months.

  11. Cohort 2, 3, 4: Additional assessments of antitumor efficacy of study intervention (Measuring DCR).

    DCR (CR+PR+SD)

    Time frame: Through study completion, up to 12 months.

  12. Cohort 2, 3, 4: Assess the population PK and intra-tumoral concentration of study intervention.

    Standard PK Parameters (Cmax) in plasma.

    Time frame: Through study completion, up to 12 months.

  13. Cohort 2, 3, 4: Assess the population PK and intra-tumoral concentration of study intervention.

    Standard PK Parameters (Tmax) in plasma

    Time frame: Through study completion, up to 12 months.

  14. Cohort 2, 3, 4: Assess the population PK and intra-tumoral concentration of study intervention.

    Standard PK Parameters (AUC) in plasma

    Time frame: Through study completion, up to 12 months.

  15. Cohort 2, 3, 4: Assess the population PK and intra-tumoral concentration of study intervention.

    Serabelisib concentration in tumor tissue

    Time frame: Through study completion, up to 12 months.

Other outcomes

  1. Cohorts 1a/1b, 2, 3, 4: Assessment of PD of study intervention.

    Change in PD markers (insulin)

    Time frame: Through study completion, up to 12 months.

  2. Cohorts 1a/1b, 2, 3, 4: Assessment of PD of study intervention.

    Change in PD markers (glucose)

    Time frame: Through study completion, up to 12 months.

  3. Cohorts 1a/1b, 2, 3, 4: Assessment of PD of study intervention.

    Change in biomarkers of insulin-PI3K signaling

    Time frame: Through study completion, up to 12 months.

  4. Cohorts 1a/1b, 2, 3, 4: Assessment of PD of study intervention.

    Changes in tumor marker levels.

    Time frame: Through study completion, up to 12 months.

  5. Cohorts 1a/1b, 2, 3, 4: Assessment of immune markers in response to study intervention.

    Assessment of immune markers in PBMCs throughout study.

    Time frame: Through study completion, up to 12 months.

  6. Cohorts 1a/1b, 2, 3, 4: Assessment of genetic predictors of efficacy.

    Analysis into whether the genetic status of the patient predicts a positive or negative therapeutic response (efficacy).

    Time frame: Through study completion, up to 12 months.

  7. Cohorts 1a/1b, 2, 3, 4: Assessment of genetic predictors of toxicity.

    Analysis into whether the genetic status of the patient predicts susceptibility to AEs (toxicity).

    Time frame: Through study completion, up to 12 months.

07

Study locations

17 sites
  • University of Alabama
    Birmingham, Alabama 35429, United States
  • Pacific Cancer Specialists
    Anaheim, California 92801, United States
  • Valkyrie Clinical Trials
    Los Angeles, California 90067, United States
  • Hoag Memorial Hospital Presbyterian
    Newport Beach, California 92663, United States
  • Community Health Network, Inc.
    Indianapolis, Indiana 46250, United States
  • Mayo Clinic - Rochester
    Rochester, Minnesota 55902, United States
  • New Jersey Cancer Care, PA
    Belleville, New Jersey 07109, United States
  • Englewood Health
    Englewood, New Jersey 07631, United States
  • Northwell Health
    Lake Success, New York 11042, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • East Carolina University
    Greenville, North Carolina 27858, United States
  • University of Pennsylvania Health System, Perelman Center for Advanced Medicine
    Philadelphia, Pennsylvania 19104, United States
  • Avera Cancer Institute
    Sioux Falls, South Dakota 57105, United States
  • Baptist Hospitals of Southeast Texas
    Beaumont, Texas 77701, United States
  • Oncology Consultants, PA
    Houston, Texas 77030, United States
  • Lumi Research
    Kingwood, Texas 77339, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2022 to primary completion in Apr 2025, 36 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2022
First posted
Mar 29, 2022
StartActual
Apr 22, 2022
Primary completionActual
Apr 30, 2025
CompletionActual
Apr 30, 2025
Last update
Apr 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05300048
Lead sponsor
Faeth Therapeutics
Responsible party
Sponsor
First posted
Mar 29, 2022
Start date
Apr 22, 2022
Primary completion
Apr 30, 2025
Completion
Apr 30, 2025
Last update
Apr 30, 2026

Study contacts

Vicky Makker
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Serabelisib

Start the discussion